Interview: Christopher Tsai, Chairman, Bionet, Taiwan
The chairman of Bionet reflects on past market challenges and the growing strength of Bionet’s reach both domestically and globally, and why Taiwan is the perfect size for a biotech…
Organization Activities
BIONET Corp. was first established in 1999 as the pioneer company in the field of stem cell application in Taiwan as well as in Asia. BIONET has focused: “Stem Cell Therapy” and “Genetic Testing”. In 2007, BIONET completed initial public offering (TPO: 1784) and became the first publicly traded company in the stem cell and genetic industry of Taiwan. Furthermore, in 2012, Genesis Genetics Asia Corp. (GGA), a subsidiary of BIONET, made its IPO (TPO: 4160) as Taiwan’s first public company specialized in both genetic testing and scientific informatics. BIONET is the largest enterprise that the penetration rate is up to 50% for cell therapy and genetic engineering industry in Taiwan.
Contact Information
Address: No.28, 36 Ln., Xinhu 1st Rd.,
Neihu Dist., Taipei City 11494
Taiwan
Phone: +886-2-2795-1777, Monday to Friday, 9am-6pm CST (UTC+8)
Toll-free: 0800-800-018
Email: service@babybanks.com
Website: www.babybanks.com
The chairman of Bionet reflects on past market challenges and the growing strength of Bionet’s reach both domestically and globally, and why Taiwan is the perfect size for a biotech…
Vantive’s Gary Wong shares insights into the company’s evolution from Baxter’s kidney care business into a standalone, vital organ therapies organisation. He discusses the challenges of building a new brand…
Dr David Chang discusses his vision for establishing the world’s premier cell and gene therapy contract development and manufacturing organisation in Taiwan. Drawing on more than 30 years of experience…
ImmunAdd’s Dr Pi-Hui Liang discusses her transition from academic research to entrepreneurship, driven by the critical shortage of commercially available vaccine adjuvants. With a proprietary saponin-based platform addressing supply chain…
Dr Ethan Shen moves comfortably between the clinic, the laboratory, and capital markets, and this conversation reflects that rare vantage point. He explains how YD Bio is built not as…
Dr John Chang, Chief Executive Officer of the Formosa Cancer Foundation and a distinguished medical oncologist at Chang Gung Memorial Hospital, provides a comprehensive strategic analysis of Taiwan’s oncology landscape.…
Jerry Cheng is general manager for Illumina across Taiwan, Hong Kong, and Macau, steering the company’s expansion in three strategically significant genomics markets. With over two decades of pharmaceutical industry…
Dr Tom Tang, CEO of Maxima, discusses the company’s strategic positioning in the surgical energy device market, Taiwan’s emerging role in global medical technology manufacturing, and his vision for creating…
Dr Jung-Chi Liao, CEO and Founder of Syncell, explains how his company is creating a new category in protein identification through its microscopy-guided protein extraction technology. Trained as a mechanical…
Since arriving at Organon Taiwan two years ago, Robert Mitchell has focused on growing patient access, revenue, and investments while strengthening the team. Robert explains how he is prioritising government…
Chung-Liang Shih, Taiwan’s Minister of Health and Welfare, brings extensive governmental experience from his tenure as Director General of the National Health Insurance Administration, where he led reforms to strengthen…
Lih-Chung Chien, Chairman of the Taipei Exchange (TPEx), highlights the Exchange’s support for SMEs and innovative sectors via a three-tiered market, flexible IPO rules, and the Technology-Based Enterprise mechanism. Taiwan’s…
Epidemiologist Dr Chen Chien-jen has spent decades at the intersection of scientific research and public health policy. His pioneering work on arsenic-induced health hazards informed international water safety standards, whilst…
See our Cookie Privacy Policy Here
